Uterine artery doppler – when would you order one?

13th February 2024, NIA Diagnostic Imaging

Uterine Artery

Commonly, uterine artery doppler ultrasound is conducted to measure the blood flow in the uterine arteries. This specific ultrasound allows for qualitative information to be gathered on the presence/absence of flow, the direction of flow, the quality of flow, to determine if the flow is laminar or turbulent and to distinguish waveform shape (low resistance, high resistance, early diastolic notch) (Naguib et al.,2012).…

Salpingectomy to prevent ovarian cancer?

27th January 2024, A/Prof Chee L Khoo

Ovaries

The World Health Organisation classifies epithelial ovarian carcinomas into several morphological categories according to cell type: serous carcinomas (SC), mucinous carcinomas, endometrioid carcinomas, and clear-cell carcinomas, transitional-cell Brenner tumours, mixed, and undifferentiated type [1]. SC account for 75-80% of epithelial carcinomas and are subdivided into high-grade SC (HGSC) and low-grade SC (LGSC). Like any other cancers, early diagnosis would be important to improve the prognosis but often when diagnosed, ovarian cancer is in its advanced stages.…

Cervical screening – hands up who’s not here?

25th November 2023, A/Prof Chee L Khoo

Cervical screening for cervical cancer for the prevention of cervical cancer has to be one of the most successful campaigns in primary care. For most, instead of having an intimate check every two years, doing it every 5 years is such a relief. For others, it is still having to endure an insertion of a vaginal speculum.…

Genetic carrier screening on MBS now – what does that mean?

25th November 2023, A/Prof Chee L Khoo

genetic carrier screening

Reproductive genetic carrier screening for cystic fibrosis (CF), spinal muscular atrophy (SMA) and fragile X syndrome (FXS) has become available on the Medicare Benefits Scheme (MBS). Screening for those three conditions is recommended for all couples prior to, or in the early stages of pregnancy. Great but what is this genetic screening all about?…

Early breast cancer – close collaboration between GP and radiologist.

13th August 2023, NIA Diagnostic Imaging

A 49-year-old lady presented with pain in her right breast. There is a strong family history of breast cancer. Breast examination was difficult because of “lumpiness” of the breasts. She was referred for a breast ultrasound at NIA. Ultrasound showed two lesions in the right breast – one at 3 o’clock, 2cm from the nipple and another at 7 o’clock, 2cm from the nipple.…

Obstetric Imaging – what scans/tests can you order?

29th June 2023, Spectrum Medical Imaging

At Spectrum Medical Imaging, we are pleased to offer your patients a wide range of obstetric imaging options throughout all stages of their pregnancy. We are committed to providing you with high quality services at affordable prices. All of our sonographers who perform Nuchal Translucency scans are certified by the Fetal Medicine Foundation and all of our reporting Radiologists have a special interest in obstetric ultrasound.…

Pelvic organ prolapse – diagnosis with translabial ultrasound

11th June 2023, NIA Diagnostic Imaging

translabial US

The incidence of pelvic organ prolapse is highly associated with increased age and vaginal childbirth (Weintraub et al., 2020). Majority of patients who present with POP may not report any symptoms. Patients who do present with symptoms, however, often describe a sense of feeling of a bulge protruding through the vaginal opening. In younger women, vaginal laxity is more commonly noticed and related to sexual dysfunction (Peter Dietz, 2015).…

TOBOGM has finally published – what has it taught us?

14th May 2023, Dr Chee L Khoo

TOBOGM is the very first study to see if immediate treatment of early gestational diabetes mellitus (GDM) increases or reduces pregnancy complications among women with GDM diagnosed with OGTT before 20 weeks’ gestation. TOBOGM study results will significantly contribute to the management decisions of pregnant women with early GDM. Campbelltown Hospital was the lead recruiting centre with Professor David Simmons being the chief investigator of this international study.…

Anthracycline-induced cardiotoxicity – can we prevent it?

1st April 2023, Dr Chee L Khoo

Cardiotoxicity

Two months ago, we explored heart failure in cancer survivors exposed to anthracyclines in a dose dependent manner. Anthracyclines are a common agents used in chemotherapy against breast cancer and lymphomas. Heart failure may appear as early as within 12 months of receiving anthracyclines and the incidence continues to grow over time. There have been a lot of work done on the possible molecular pathways in the development of the cardiotoxicity, the prevention strategies explored and the development of “safer” anthracycline derivatives.…

Uterine fibroids – another treatment option

Spectrum Medical Imaging, 28th February 2023

Uterine fibroids

Uterine fibroids are benign (non-cancerous) tumours of the
uterus. They are clinically apparent in up to 25% of women
and, with newer imaging techniques, the true clinical
prevalence may be higher (up to 77% ). Although most do
not cause symptoms, uterine fibroids can cause severe
problems for some women who have the condition.…

Different breasts, different densities hence, different screening techniques

29th January 2023, Spectrum Medical Imaging

Breasts not only come in different sizes and shapes but have different composition and densities. The breast density also changes with age, body composition and genetic factors. 50% of women in the US have dense breasts and dense breast tissue can camouflage early breast cancer. Yet, we only have standardised mammography and screening schedules. The Volpara is an AI software platform that provides an individualised risk assessment and screening recommendations based on the composition of the breast of the woman.…